

**EISAI TO PRESENT NEW RESEARCH ON HALAVEN[®] (ERIBULIN)
AT 37TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that new clinical study results on the company's novel anticancer agent Halaven[®] (eribulin mesylate) will be presented during the 37th San Antonio Breast Cancer Symposium (SABCS). The symposium will be held from December 9 through 13, 2014, in